BIOMAT Database Logo BIOMAT Database Logo

Preclinical pharmacokinetics and biodistribution of subcutaneously administered glycoPEGylated recombinant factor VIII (N8-GP) and development of a human pharmacokinetic prediction model. 2018

F Rode, and K Almholt, and M Petersen, and M Kreilgaard, and M Kjalke, and D M Karpf, and A V Groth, and P B Johansen, and L F Larsen, and M Loftager, and J Haaning
Global Research, Novo Nordisk A/S, Måløv, Denmark.

Essentials N8-GP is an extended half-life recombinant factor VIII (FVIII) for the treatment of hemophilia A. Subcutaneous (SC) FVIII dosing might reduce the treatment burden of prophylaxis. SC N8-GP has a favorable PK profile in animal models and disappears from skin injection sites. Combined animal (SC) and clinical (IV) data suggest that daily SC dosing may provide prophylaxis. Background N8-GP is an extended half-life recombinant factor VIII (FVIII) for the treatment of hemophilia A. Subcutaneous administration of FVIII may reduce the treatment burden of prophylaxis; however, standard FVIII products have low bioavailability after subcutaneous dosing in animals. Objective To evaluate the pharmacokinetics, effectiveness and local distribution of subcutaneously administered N8-GP in preclinical models and predict the human pharmacokinetic (PK) profile. Methods The pharmacokinetics of subcutaneously administered N8-GP were evaluated in FVIII knockout (F8-KO) mice and cynomolgus monkeys; a human PK prediction model in hemophilia A patients was developed. The hemostatic effect was evaluated in a tail vein bleeding model in F8-KO mice. The injection-site distribution and absorption of subcutaneously administered N8-GP were assessed in F8-KO mice by the use of temporal fluorescence imaging and immunohistochemistry. Results Subcutaneously administered N8-GP had a bioavailability, a first-order absorption rate and a half-life, respectively, of 24%, 0.094 h-1 and 14 h in F8-KO mice, and 26%, 0.33 h-1 and 15 h in cynomolgus monkeys. A dose-dependent effect of subcutaneously administered N8-GP on blood loss was observed in mice. A minimal amount of N8-GP was detected at the injection site 48-72 h after single or multiple dose(s) in F8-KO mice. Subcutaneously administered N8-GP was localized to the skin around the injection site, with time-dependent disappearance from the depot. PK modeling predicted that subcutaneously administered N8-GP at a daily dose of 12.5 IU kg-1 will provide FVIII trough levels of 2.5-10% in 95% of patients with severe hemophilia A. Conclusions Subcutaneously administered N8-GP may provide effective hemophilia A prophylaxis. A phase I clinical trial is underway to investigate this possibility.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007279 Injections, Subcutaneous Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin. Subcutaneous Injections,Injection, Subcutaneous,Subcutaneous Injection
D008252 Macaca fascicularis A species of the genus MACACA which typically lives near the coast in tidal creeks and mangrove swamps primarily on the islands of the Malay peninsula. Burmese Long-Tailed Macaque,Crab-Eating Monkey,Cynomolgus Monkey,M. f. aurea,M. fascicularis,Macaca fascicularis aurea,Monkey, Crab-Eating,Monkey, Cynomolgus,Crab-Eating Macaque,Burmese Long Tailed Macaque,Crab Eating Macaque,Crab Eating Monkey,Crab-Eating Macaques,Crab-Eating Monkeys,Cynomolgus Monkeys,Long-Tailed Macaque, Burmese,Macaque, Burmese Long-Tailed,Macaque, Crab-Eating,Monkey, Crab Eating
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D011092 Polyethylene Glycols Polymers of ETHYLENE OXIDE and water, and their ethers. They vary in consistency from liquid to solid depending on the molecular weight indicated by a number following the name. They are used as SURFACTANTS, dispersing agents, solvents, ointment and suppository bases, vehicles, and tablet excipients. Some specific groups are NONOXYNOLS, OCTOXYNOLS, and POLOXAMERS. Macrogols,Polyoxyethylenes,Carbowax,Macrogol,Polyethylene Glycol,Polyethylene Oxide,Polyethyleneoxide,Polyglycol,Glycol, Polyethylene,Glycols, Polyethylene,Oxide, Polyethylene,Oxides, Polyethylene,Polyethylene Oxides,Polyethyleneoxides,Polyglycols,Polyoxyethylene
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D005169 Factor VIII Factor VIII of blood coagulation. Antihemophilic factor that is part of the factor VIII/von Willebrand factor complex. Factor VIII is produced in the liver and acts in the intrinsic pathway of blood coagulation. It serves as a cofactor in factor X activation and this action is markedly enhanced by small amounts of thrombin. Coagulation Factor VIII,Factor VIII Clotting Antigen,Factor VIII Coagulant Antigen,Factor VIII Procoagulant Activity,Thromboplastinogen,Blood Coagulation Factor VIII,F VIII-C,Factor 8,Factor 8 C,Factor Eight,Factor VIIIC,Hyate-C,Hyatt-C,F VIII C,Hyate C,HyateC,Hyatt C,HyattC
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006467 Hemophilia A The classic hemophilia resulting from a deficiency of factor VIII. It is an inherited disorder of blood coagulation characterized by a permanent tendency to hemorrhage. Factor VIII Deficiency,Hemophilia,Autosomal Hemophilia A,Classic Hemophilia,Deficiency, Factor VIII,Factor 8 Deficiency, Congenital,Factor VIII Deficiency, Congenital,Haemophilia,Hemophilia A, Congenital,Hemophilia, Classic,As, Autosomal Hemophilia,Autosomal Hemophilia As,Classic Hemophilias,Congenital Hemophilia A,Congenital Hemophilia As,Hemophilia A, Autosomal,Hemophilia As,Hemophilia As, Autosomal,Hemophilia As, Congenital,Hemophilias, Classic
D006490 Hemostatics Agents acting to arrest the flow of blood. Absorbable hemostatics arrest bleeding either by the formation of an artificial clot or by providing a mechanical matrix that facilitates clotting when applied directly to the bleeding surface. These agents function more at the capillary level and are not effective at stemming arterial or venous bleeding under any significant intravascular pressure. Antihemorrhagic,Hemostatic,Antihemorrhagics

Related Publications

F Rode, and K Almholt, and M Petersen, and M Kreilgaard, and M Kjalke, and D M Karpf, and A V Groth, and P B Johansen, and L F Larsen, and M Loftager, and J Haaning
Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A.
April 2013, Journal of thrombosis and haemostasis : JTH,
F Rode, and K Almholt, and M Petersen, and M Kreilgaard, and M Kjalke, and D M Karpf, and A V Groth, and P B Johansen, and L F Larsen, and M Loftager, and J Haaning
Measuring FVIII activity of glycopegylated recombinant factor VIII, N8-GP, with commercially available one-stage clotting and chromogenic assay kits: a two-centre study.
May 2017, Haemophilia : the official journal of the World Federation of Hemophilia,
F Rode, and K Almholt, and M Petersen, and M Kreilgaard, and M Kjalke, and D M Karpf, and A V Groth, and P B Johansen, and L F Larsen, and M Loftager, and J Haaning
Once-weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8-GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial).
May 2019, Haemophilia : the official journal of the World Federation of Hemophilia,
F Rode, and K Almholt, and M Petersen, and M Kreilgaard, and M Kjalke, and D M Karpf, and A V Groth, and P B Johansen, and L F Larsen, and M Loftager, and J Haaning
N8-GP: A new extended half-life recombinant factor VIII product for hemophilia A.
September 2020, Journal of thrombosis and haemostasis : JTH,
F Rode, and K Almholt, and M Petersen, and M Kreilgaard, and M Kjalke, and D M Karpf, and A V Groth, and P B Johansen, and L F Larsen, and M Loftager, and J Haaning
Safety and pharmacokinetics of subcutaneously administered recombinant activated factor VII (rFVIIa).
June 2011, Journal of thrombosis and haemostasis : JTH,
F Rode, and K Almholt, and M Petersen, and M Kreilgaard, and M Kjalke, and D M Karpf, and A V Groth, and P B Johansen, and L F Larsen, and M Loftager, and J Haaning
Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX.
November 2012, Journal of thrombosis and haemostasis : JTH,
F Rode, and K Almholt, and M Petersen, and M Kreilgaard, and M Kjalke, and D M Karpf, and A V Groth, and P B Johansen, and L F Larsen, and M Loftager, and J Haaning
Purification and characterization of a new recombinant factor VIII (N8).
March 2010, Haemophilia : the official journal of the World Federation of Hemophilia,
F Rode, and K Almholt, and M Petersen, and M Kreilgaard, and M Kjalke, and D M Karpf, and A V Groth, and P B Johansen, and L F Larsen, and M Loftager, and J Haaning
Prolonged effect of a new O-glycoPEGylated FVIII (N8-GP) in a murine saphenous vein bleeding model.
November 2013, Haemophilia : the official journal of the World Federation of Hemophilia,
F Rode, and K Almholt, and M Petersen, and M Kreilgaard, and M Kjalke, and D M Karpf, and A V Groth, and P B Johansen, and L F Larsen, and M Loftager, and J Haaning
A pharmacokinetic model for alpha interferon administered subcutaneously.
April 1999, British journal of clinical pharmacology,
F Rode, and K Almholt, and M Petersen, and M Kreilgaard, and M Kjalke, and D M Karpf, and A V Groth, and P B Johansen, and L F Larsen, and M Loftager, and J Haaning
Prediction of human pharmacokinetics of activated recombinant factor VII and B-domain truncated factor VIII from animal population pharmacokinetic models of haemophilia.
March 2018, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences,
Copied contents to your clipboard!